Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Martin Anne-Marie				<u>C</u>	2. Issuer Name and Ticker or Trading Symbol Cullinan Therapeutics, Inc. [CGEM]					(Ch	elationship of eck all applications.	,	erson(s) to Iss 10% Ov		
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/26/2024							Officer below)	(give title	Other (s below)	specify
C/O CULLINAN THERAPEUTICS, INC. ONE MAIN STREET, SUITE 1350				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person				
(Street)	IDGE M	· A	02142	-									iled by More th		- 1
CAMBRIDGE MA 02142			_ R	Rule 10b5-1(c) Transaction Indication											
(City)	(S	tate)	(Zip)					licate that a tran					n or written plan	that is intended	i to
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Transa Date (Month/Date)				Execution Date,		Code (Ins	ransaction Disposed Of (D) (Instr. 3, ode (Instr. 5)			Beneficia	es For ally (D) following (I)	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	Amount	(A) or (D)	Price	Transact (Instr. 3	ion(s)		(111541. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		Date Exec (Month/Day/Year) if an	3A. Deemed Execution Date, if any (Month/Day/Year)		Transaction (Code (Instr. I)		ive ies ed ed nstr. i 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$16.5	06/26/2024		A		15,806		(1)	06/26/2034	Common Stock	15,806	\$0.00	15,806	D	

Explanation of Responses:

1. The option represents a right to purchase a total of 15,806 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 26, 2025 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date

/s/ Jacquelyn Sumer, Attorney-

in-Fact

** Signature of Reporting Person Date

06/2<u>7/2024</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.